In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...

Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated ...

The FDA issued draft guidance Jan. 21 proposing the use of minimal residual disease and complete response as primary endpoints to support accelerated approval of drugs for multiple myeloma. The draft ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Key abstracts on multiple myeloma from the 2025 American Society of Hematology Annual Meeting are reported by Dr Joseph Mikhael, chief medical officer of the International Myeloma Foundation. Dr ...

In a move that could dramatically shorten some clinical development timelines for drugs targeting multiple myeloma, the U.S. FDA issued a draft guidance on the potential use of minimal residual ...

The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...

Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...

Rose was diagnosed with multiple myeloma in August 2024. Now on an upward path in her cancer journey, she is focused on ...